Mechanism-based perspective on metal ion-induced signal instability and development of a robust LC-MS/MS method for trace quantification of hetrombopag in plasma

Article

Author: Chen, Jiao ; Wang, Jie ; Dai, Biying ; Wang, Xiaoli ; Han, Jiangbin ; Wu, Yuyu ; Lu, Huiyue ; Zhai, Lijuan ; Qian, Wen

Hetrombopag (Hengqu®) is an oral nonpeptide thrombopoietin receptor agonist for the treatment of thrombocytopenia and aplastic anemia. Research on the pharmacokinetic behavior is very important, but accurate quantification of metal-sensitive hetrombopag in biological specimens is a challenging analytical problem. In view of the presence of trace metals from a variety of sources, such as chromatographic system, containers, and the mass spectrometry spray needle, which can contribute to poor peak shape, tailing, and diminished recovery of compound. To ameliorate these problems, different solvent additives, mobile phase, containers and precipitant reagents were investigated to reduce the negative effects. In the present study, a robust, selective, and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the determination of hetrombopag in dog plasma was developed based on the dual strategies: (1) 6 % perchloric acid in acetonitrile eliminates metal ion adsorption in storage containers, and (2) 0.01 % trifluoroacetic acid (TFA) in the mobile phase suppresses chelation in chromatographic systems. These two solvents are essential requirements for ensuring stable analytical signals. This method employed an InfinityLab Poroshell 120 EC-C18 column (4.6 ×50 mm, 2.7 μm, Agilent) with a gradient system comprising 0.01 % trifluoroacetic acid with 10 mM ammonium formate (phase A) and a mixture of H₂O: methanol: isopropanol (1:10:10, v/v/v) containing 0.01 % trifluoroacetic acid and 10 mM ammonium formate (phase B). The column temperature of 50℃ and the addition of isopropanol were beneficial for the separation of interfering peaks and target analyte peaks in plasma. The method exhibits excellent linearity over 3 orders of magnitude. The method achieved a lower limit of quantification (LLOQ) of 0.10 ng/mL using only 50 μL of plasma, with precision (RSD ≤ 8.83 %) and accuracy (88.4-102.2 %) within acceptable limits. The method was applied to determine the plasma concentration of hetrombopag in eight male beagle dogs after each administration of three 2.5 mg hetrombopag tablets. The analytical methodology described in the present work should be useful in the future work aiming to establish a model relating metal-sensitive other compounds.

01 Oct 2025·INTERNATIONAL JOURNAL OF HEMATOLOGY

A phase 3 study of the efficacy and safety of avatrombopag in Japanese adults with chronic immune thrombocytopenia

Article

Author: Jamieson, Brian D ; Yokoyama, Kenji ; Yamanouchi, Jun ; Tomiyama, Yoshiaki ; Ishikawa, Tatsunori ; Imamura, Yutaka ; Kowata, Shugo ; Kirito, Keita ; Ito, Tomoki ; Zhang, Jessica ; Shiratsuchi, Motoaki ; Yamaguchi, Hiroki ; Iino, Masaki ; Yamamoto, Ryusuke ; Kamiya, Harumi

Abstract:

Avatrombopag is an oral thrombopoietin receptor agonist approved widely for the treatment of adults with chronic immune thrombocytopenia (ITP). However, data in Japanese patients are limited. This confirmatory phase 3, open-label study investigated avatrombopag (initial dose 20 mg/day) in Japanese adults (aged ≥ 18 years) with chronic ITP (≥ 12 months), insufficient response to prior treatment and an average of 2 platelet counts (PCs) < 30 × 109/L. The primary endpoint was the cumulative number of weeks of platelet response (PC ≥ 50 × 109/L) without rescue therapy for bleeding. Secondary endpoints included platelet response rate at Day 8 and safety. In total, 19 patients were enrolled into the 26-week core phase. The mean age was 56.0 years; 78.9% of patients were female. Mean cumulative number of weeks of platelet response was 13.5 (95% CI 9.1–17.8). Platelet response at Day 8 was achieved by 63.2% of patients. In the core phase, adverse events (AEs) occurred in 94.7% of patients and serious AEs in 15.8%. No thromboembolic events or deaths occurred in the core phase. Avatrombopag demonstrated a rapid and durable platelet response and was well tolerated in Japanese patients with chronic ITP. Long-term safety and efficacy are being assessed in the ongoing extension phase.

01 Sep 2025·AMERICAN JOURNAL OF HEMATOLOGY

Efficacy and Safety of Hetrombopag Versus Thrombopoietin in Promoting Platelet Engraftment After Allogeneic Hematopoietic Stem Cell Transplantation: A Prospective, Multicenter, Randomized Controlled Clinical Trial

Article

Author: Chen, Ting ; Zhao, Lu ; Wang, Dan ; Feng, Yimei ; Wang, Lu ; Ma, Liangliang ; Xing, Hongyun ; Deng, Jianchuan ; Zhu, Lidan ; Wang, Sanbin ; Yao, Han ; Wang, Xiaoqi ; Wang, Xiaoning ; Zhang, Xi ; Gao, Lei ; Liu, Huanfeng ; He, Pengcheng ; Ren, Mingqiang ; Yi, Hai ; Liu, Jia ; Wang, Linhui ; Tang, Shuhan ; Liu, Yuqing ; Lang, Tao ; Li, Li ; Gao, Shichun ; Kong, Peiyan ; Wang, Jishi ; Lou, Shifeng

ABSTRACT:

Allogeneic hematopoietic stem cell transplantation (allo‐HSCT) is pivotal for hematological malignancies but faces challenges in delayed platelet engraftment, poor graft function (PGF), and bleeding risks. Hetrombopag, a thrombopoietin receptor agonist, was evaluated to enhance platelet recovery posttransplant. Patients undergoing allo‐HSCT were randomized on Day 3 Post‐Infusion into low‐dose (2.5 mg/day), high‐dose (5 mg/day) hetrombopag groups, or a control group receiving thrombopoietin (300 U/kg/day). Endpoints included platelet/neutrophil engraftment time, PGF incidence, transfusion needs, and safety. Among 212 analyzed patients, platelet engraftment was faster in hetrombopag groups (median 13 days) versus controls (15 days; p = 0.0022), with no dose‐dependent difference (p = 0.0593). Neutrophil engraftment was also accelerated (13 vs. 15 days; p = 0.0001). PGF incidence was lower in hetrombopag groups (5.04%) versus controls (13.7%; p = 0.027). The experimental group required fewer platelet transfusions (p = 0.002), had reduced gastrointestinal bleeding, and lower costs. Secondary platelet recovery failure showed no intergroup differences. Hetrombopag safely accelerates platelet and neutrophil engraftment, reduces PGF risk, and decreases transfusion dependency post‐allo‐HSCT. Low‐dose hetrombopag demonstrated efficacy equivalent to high‐dose, offering a cost‐effective strategy to improve transplant outcomes.Trial Registration: ChiCTR2200057764.

News (Medical) associated with Thrombopoietin agonist(The Scripps Research Institute)

12 Dec 2024

·www.globenewswire.com

Sobi Announces FDA Acceptance of New Drug Application for Avatrombopag (DOPTELET®) for the Treatment of Pediatric Immune Thrombocytopenia

Avatrombopag PDUFA date set for July 24, 2025WALTHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi®), today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for avatrombopag (DOPTELET®) for the treatment of thrombocytopenia in pediatric patients one year and older with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to a prior therapy. The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date of July 24, 2025. The FDA also accepted Sobi’s New Drug Application (NDA) for avatrombopag for oral suspension. Avatrombopag for oral suspension is a capsule where its granules are sprinkled onto a soft food or liquid to prepare for administration. “These application acceptances for avatrombopag brings us one step closer to much-needed, additional treatment options for adolescents and children with persistent and chronic ITP,” said Jamie Freedman, MD, PhD, Chief Medical Officer, Sobi North America. “Now, there’s an opportunity to address an unmet need in our pediatric population, with the added bonus of an additional formulation, an oral suspension option that may be more suitable for some patients.” The application is based on results from the AVA-PED-301 study, evaluating the efficacy and safety of avatrombopag for the treatment of pediatric patients with ITP of at least 6 months’ duration. The study met the primary endpoint of durable platelet response defined as the proportion of patients achieving at least six out of eight weekly platelet counts ≥50×109/L during the last eight weeks of the 12-week treatment period in the core phase in the absence of rescue medication. The alternative primary efficacy endpoint of two consecutive PC ≥50× 109 /L was also met. ContactsFor details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media, click here. About immune thrombocytopeniaImmune thrombocytopenia (ITP) is an autoimmune disorder characterized by low numbers of platelets that results in an increased risk of bleeding. Symptoms can be highly variable and include bruising, a rash of small dots that represent small hemorrhages, bleeding from the gums or nose, blood in the urine/stools and debilitating fatigue. It is estimated that up to 100 people per million live with ITP. The disorder is considered chronic when symptoms last more than 12 months.i Long-term, primary chronic ITP is associated with increased risk of infections, bleeding episodes requiring hospitalization, hematologic malignancies, and mortality. No cure is available, and patients with chronic ITP usually relapse after various treatments and still require treatment to reduce the risk of clinically significant bleeding. About DOPTELET (avatrombopag)DOPTELET is an orally bioavailable, small molecule thrombopoietin receptor agonist (TPO-RA) that stimulates the proliferation and differentiation of megakaryocytes from bone marrow progenitor cells, resulting in increased production of platelets. DOPTELET does not compete with TPO for binding to the TPO receptor. INDICATION DOPTELET® (avatrombopag) is is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. IMPORTANT SAFETY INFORMATION Thrombotic/Thromboembolic Complications. DOPTELET is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic complications in patients with chronic liver disease (0.4%; (1/274) in DOPTELET-treated patients) and thromboembolic complications in patients with chronic immune thrombocytopenia (7%; (9/128) in DOPTELET-treated patients). Portal vein thrombosis has been reported in patients with chronic liver disease, and thromboembolic events (arterial and venous) have been reported in patients with chronic immune thrombocytopenia treated with TPO receptor agonists. Consider the potential increased thrombotic risk when administering DOPTELET to patients with known risk factors for thromboembolism, including genetic prothrombotic conditions and acquired risk factors. DOPTELET should not be administered to patients with chronic liver disease or chronic immune thrombocytopenia in an attempt to normalize platelet counts. Monitor platelet counts, and for signs and symptoms of thromboembolic events and institute treatment promptly. Serious Adverse Reactions Serious adverse reaction that occurred more frequently in patients treated with DOPTELET (9%; 12/128) compared to placebo (5%; 1/22) was headache, occurring in 1.6% (2/128). Adverse Reactions The most common adverse reactions (≥10%) in patients with chronic immune thrombocytopenia were headache, fatigue, contusion, epistaxis, upper respiratory tract infection, arthralgia, gingival bleeding, petechiae, and nasopharyngitis. About Sobi North America As the North American affiliate of international biopharmaceutical company Sobi, the Sobi North America team is committed to Sobi’s vision of being a leader in providing innovative treatments that transform lives for individuals with rare diseases. Our product portfolio includes multiple approved treatments focused on immunology, hematology and specialty care. With U.S. headquarters in the Boston area, Canadian headquarters in the Toronto area, and field sales, medical and market access representatives spanning North America, our growing team has a proven track record of commercial excellence. More information is available at https://www.sobi.com/usa or at www.sobi.com. About Sobi®Sobi is a specialized international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of hematology, immunology and specialty care, Sobi has approximately 1,800 employees across Europe, North America, the Middle East, Asia and Australia. In 2023, revenue amounted to SEK 22.1 billion. Sobi’s share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com, LinkedIn and YouTube.

Clinical ResultNDAImmunotherapy

02 Jul 2024

·www.biospace.com

Gyre Therapeutics Announces China’s NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia

SAN DIEGO, July 02, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced that China’s National Medical Products Administration (“NMPA”) has approved Gyre Pharmaceuticals’ (Gyre’s indirectly controlled subsidiary) avatrombopag maleate tablets for the treatment of thrombocytopenia (“TP”) associated with chronic liver disease (“CLD”) in adult patients undergoing elective diagnostics procedures or therapy. TP is the most common hematologic complication in patients with CLD and can be life threatening in severe cases. “The approval of avatrombopag maleate tablets by the NMPA represents an important milestone for Gyre as we expand our rare disease product lines and build our presence in developing treatments for patients with CLD,” said Han Ying, Ph.D., CEO of Gyre Therapeutics. “We are eager to launch avatrombopag in China and provide a treatment for patients suffering from this devastating disease.” Gyre Pharmaceuticals acquired avatrombopag under a transfer agreement with Nanjing Healthnice Pharmaceutical Technology Co., Ltd. (“Nanjing Healthnice”) in June 2021. Avatrombopag is an oral thrombopoietin receptor agonist (“TPO-RA”). Avatrombopag was approved by the U.S. Food and Drug Administration (“FDA”) for the treatment of adults with CLD-associated TP in May 2018, and its indication was subsequently expanded to include the treatment of immune thrombocytopenia in June 2019. About Gyre Therapeutics Gyre Therapeutics is a biopharmaceutical company headquartered in San Diego, CA, with a primary focus on the development and commercialization of F351 (Hydronidone) for the treatment of NASH-associated fibrosis in the U.S. Gyre’s development strategy for F351 in NASH is based on the company’s experience in NASH rodent model mechanistic studies and CHB-induced liver fibrosis clinical studies. Gyre is also advancing a diverse pipeline in the PRC through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this press release, are forward-looking statements, including statements concerning: expectations regarding Gyre’s research and development efforts, including the expansion of its rare disease pipeline; expectations regarding avatrombopag maleate tablets, including its therapeutic effectiveness and potential marketing opportunities; expectations regarding future product sales; expectations and Gyre’s financial position and cash resources. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “plan” or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements reflect our plans, estimates, and expectations as of the date of this press release. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this press release. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation: Gyre’s ability to execute on its clinical development strategies; competition from competing products; the impact of general economic, health, industrial or political conditions in the United States or internationally; and the sufficiency of Gyre’s capital resources and its ability to raise additional capital. Additional risks and factors are identified under “Risk Factors” in Gyre’s Annual Report on Form 10-K for the year ended December 31, 2023 filed on March 27, 2024, and in other filings with the Securities and Exchange Commission. Gyre expressly disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. For Investors: Stephen Jasper stephen@gilmartinir.com

Drug ApprovalAcquisition

17 Apr 2023

·www.businesswire.com

Immune Thrombocytopenia (ITP) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape 2023 - ResearchAndMarkets.com

DUBLIN--( BUSINESS WIRE )--The "Immune Thrombocytopenia (ITP) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape" report has been added to ResearchAndMarkets.com's offering. This reports provides a data-driven overview of the current and future competitive landscape in ITP therapeutics. Key Highlights There will be more than 1.6 million diagnosed prevalent cases of ITP in 2023 across 16 pharmaceutical markets. There are four leading marketed innovator drugs for the treatment of ITP, majority of marketed products are thrombopoietin receptor agonist. R&D activity in ITP is significant, with nine products in Phase III development. Novartis has sponsored the highest number of clinical trials (nine) in ITP over the past 10 years. In deals involving ITP assets, licensing agreements are the most common type of deal globally. New innovator drugs are expected to enter the ITP market only after the next two years. Scope The publisher's Immune Thrombocytopenia (ITP) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace. Components of the report include: Disease Landscape Disease Overview Epidemiology Overview Treatment Overview Marketed Products Assessment Breakdown by Mechanism of Action, Molecule Type, Route of Administration Product Profiles with Sales Forecast Pricing and Reimbursement Assessment Retail or Manufacturer Price of Products Time to Pricing and Time to Reimbursement Pipeline Assessment Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration Product Profiles with Sales Forecast Late-to-mid-stage Pipeline Drugs Phase Transition Success Rate and Likelihood of Approval Clinical Trials Assessment Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status Enrolment Analytics, Site Analytics, Feasibility Analysis Deals Landscape Mergers, Acquisitions, and Strategic Alliances by Region Overview of Recent Deals Commercial Assessment Key Market Players Future Market Catalysts Reasons to Buy Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Develop business strategies by understanding the trends shaping and driving the ITP market. Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global ITP market in the future. Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships. Key Topics Covered: 1 Preface 1.1 Contents 1.2 Report Scope 1.3 List of Tables and Figures 1.4 Abbreviations 2 Key Findings 3 Disease Landscape 3.1 Disease Overview 3.2 Epidemiology Overview 3.3 Treatment Overview 4 Marketed Drugs Assessment 4.1 Leading Marketed Drugs 4.2 Overview by Mechanism of Action 4.3 Overview by Route of Administration 4.4 Marketed Drugs Profiles and Sales Forecasts 5 Pricing and Reimbursement Assessment 5.1 Manufacturer Price 5.2 Time to Pricing and Reimbursement 6 Pipeline Drugs Assessment 6.1 Phase III Pipeline Drugs 6.2 Overview by Development Stage 6.3 Overview by Molecule Type 6.4 Overview by Mechanism of Action 6.5 Overview by Route of Administration 6.6 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA) 6.7 Therapy Area and Indication-specific PTSR and LoA 7 Clinical Trials Assessment 7.1 Historical Overview 7.2 Overview by Phase 7.3 Overview by Status 7.4 Overview by Phase for Ongoing and Planned Trials 7.5 Trials with Virtual Components 7.6 Geographic Overview 7.7 Single-Country and Multinational Trials by Region 7.8 Top 20 Sponsors with Breakdown by Phase 7.9 Top 20 Sponsors with Breakdown by Status 7.10 Overview by Endpoint Status 7.11 Overview by Race and Ethnicity 7.12 Enrollment Data 7.13 Top 20 countries for Trial Sites 7.14 Top 20 Sites Globally 7.15 Feasibility Analysis - Geographic Overview 7.16 Feasibility Analysis - Benchmark Models 8 Deals Landscape 8.1 Mergers, Acquisitions, and Strategic Alliances by Region 8.2 Recent Mergers, Acquisitions, and Strategic Alliances 9 Commercial Assessment 9.1 Key Market Players 10 Future Market Catalysts 11 Appendix For more information about this report visit https://www.researchandmarkets.com/r/rmu1tn Source: GlobalData About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Phase 3

100 Deals associated with Thrombopoietin agonist(The Scripps Research Institute)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Thrombocytopenia	Clinical	-	The Scripps Research Institute	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EHA2024	Not Applicable	Purpura, Thrombocytopenic, Idiopathic	116	Romiplostim	npstmeegeu(bqtmklqeed) = dxtkeykdto jisxgywskd (bcbojleroi )	-	14 May 2024
				Eltrombopag	npstmeegeu(bqtmklqeed) = nbpvzhqmxj jisxgywskd (bcbojleroi )
EHA2024	Not Applicable	Refractory Severe Aplastic Anemia	366	Intensive Immunosuppressive Therapy (IST) alone	mdszvspilg(wcnillebdo) = evbsafabrz hfdxthrqth (ybkriduyuw ) View more	Positive	14 May 2024
				Intensive Immunosuppressive Therapy (IST) + Thrombopoietin Receptor Agonist (TPO-RA)	mdszvspilg(wcnillebdo) = wewrpnddeo hfdxthrqth (ybkriduyuw ) View more
ISTH2023	Not Applicable	Purpura, Thrombocytopenic, Idiopathic	8	TPO-RA + Rituximab	ibhqwhmxbr(ofjzflnmxz) = tnfqfmslmg lejihylitz (tnjqifbtni ) View more	-	24 Jun 2023
EHA2023	Not Applicable	Purpura, Thrombocytopenic, Idiopathic	211	TPO-RAs	jkipqcdjbe(heiqrwhfao) = frtwkgpcqr excbmudvmp (piqxizaqqy )	-	08 Jun 2023
EHA2023	Not Applicable	Purpura, Thrombocytopenic, Idiopathic Second line	96	Eltrombopag	ggwkpvvone(xdqiazuytd) = gnoevvxcvq crfypahzvx (origpyqnpf )	-	08 Jun 2023
EHA2022	Not Applicable	Purpura, Thrombocytopenic, Idiopathic	166	Romiplostim	hygkqmnxxt(cifhwkhhhm) = Thrombocytosis was noted in 12 (7%) patients with no evidence of thrombosis, and 2 (1%) patients progressed to myelodysplastic syndrome. sqokwcikrl (fowlibwqmm )	-	12 May 2022
				Eltrombopag
EHA2020	Not Applicable	Purpura, Thrombocytopenic, Idiopathic Second line	6	Eltrombopag	umisvimnga(pvpaxmnyso) = one of them also complained of headache wdbkkwlnsi (plziuzjnjp ) View more	Positive	14 May 2020
EHA2019	Not Applicable	Purpura, Thrombocytopenic, Idiopathic	194	Romiplostim	rnubbasfaf(pakeiwclhd) = qmobkkxtjc ikjyrszhrs (viypfaymzu, 20 - 276)	-	14 Jun 2019
				Eltrombopag	rnubbasfaf(pakeiwclhd) = domjhklbzn ikjyrszhrs (viypfaymzu, 13 - 131)
EHA2017	Not Applicable	Purpura, Thrombocytopenic, Idiopathic First line	38	Romiplostim	duvlnyrhsr(pkauvtidon) = only one case of eltrombopag suspension because of a thromboembolic event awnujubplz (lwlhzappht )	-	18 May 2017
				Eltrombopag
EHA2017	Not Applicable	Refractory Thrombocytopenia	20	Romiplostim	yaftuvqyjb(khjakjurzd) = 1/15 pt presented hemolytic anemia ifwysudpcm (gaevorkfpu ) View more	-	18 May 2017

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Thrombopoietin agonist(The Scripps Research Institute)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation